Dr. Chris Brady, WCG VeraSci’s VP, Clinical Science, will present a poster on treating behavioral symptoms in patients with Fragile X Syndrome during the NORD Rare Summit 2021.
Register today to access the Nord Summit virtual event platform and the poster, “Design of a Phase 3 Trial of ZYN002 Cannabidiol Transdermal Gel in Children and Adolescents with Fragile X Syndrome Based Upon Learnings from CONNECT-FX (ZYN2-CL-016)”.
The National Organization for Rare Disorders (NORD) is a patient advocacy organization dedicated to individuals with rare diseases and the organizations that serve them. Through the NORD Summit, members of the global rare disease community share new insights, discuss critical topics in the rare disease field, and network with rare disease experts, leaders in patient advocacy, industry, government, and academia.
If you have questions about Dr. Brady’s work in rare diseases or would like to know how WCG VeraSci can provide support for an upcoming rare disease clinical trial, please reach out to our team to set up a meeting.